Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1517/17460441.2016.1153625 http://scihub22266oqcxt.onion/10.1517/17460441.2016.1153625 C4933595!4933595 !26901465     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26901465 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Expert+Opin+Drug+Discov 2016 ; 11 (4 ): 407-14 Nephropedia Template TP {{tp|p=26901465 |t=2016. Novel approaches to pulmonary arterial hypertension drug discovery |pdf=|usr=}}{{26901465 }} gab.com Text Novel approaches to pulmonary arterial hypertension drug discovery JO: Expert Opin Drug Discov http://www.kidney.de/pget.php?&tw=1&pmid=26901465 #FOAvip INTRODUCTION: Pulmonary arterial hypertension (PAH) is a rare disorder associated with abnormally elevated pulmonary pressures that, if untreated, leads to right heart failure and premature death. The goal of drug development for PAH is to develop effective therapies that halt, or ideally, reverse the obliterative vasculopathy that results in vessel loss and obstruction of blood flow to the lungs. AREAS COVERED: This review summarizes the current approach to candidate discovery in PAH and discusses the currently available drug discovery methods that should be implemented to prioritize targets and obtain a comprehensive pharmacological profile of promising compounds with well-defined mechanisms. EXPERT OPINION: To improve the successful identification of leading drug candidates, it is necessary that traditional pre-clinical studies are combined with drug screening strategies that maximize the characterization of biological activity and identify relevant off-target effects that could hinder the clinical efficacy of the compound when tested in human subjects. A successful drug discovery strategy in PAH will require collaboration of clinician scientists with medicinal chemists and pharmacologists who can identify compounds with an adequate safety profile and biological activity against relevant disease mechanisms. Twit Text FOAVip Novel approaches to pulmonary arterial hypertension drug discovery ????Expert Opin Drug Discov http://www.kidney.de/pget.php?&tw=1&pmid=26901465 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26901465 #FOAvip English Wikipedia <ref>{{Cite pmid|26901465 }}</ref> Novel approaches to pulmonary arterial hypertension drug discovery #MMPMID26901465 Sung YK ; Yuan K ; de Jesus Perez VA Expert Opin Drug Discov 2016[]; 11 (4 ): 407-14 PMID26901465 show ga INTRODUCTION: Pulmonary arterial hypertension (PAH) is a rare disorder associated with abnormally elevated pulmonary pressures that, if untreated, leads to right heart failure and premature death. The goal of drug development for PAH is to develop effective therapies that halt, or ideally, reverse the obliterative vasculopathy that results in vessel loss and obstruction of blood flow to the lungs. AREAS COVERED: This review summarizes the current approach to candidate discovery in PAH and discusses the currently available drug discovery methods that should be implemented to prioritize targets and obtain a comprehensive pharmacological profile of promising compounds with well-defined mechanisms. EXPERT OPINION: To improve the successful identification of leading drug candidates, it is necessary that traditional pre-clinical studies are combined with drug screening strategies that maximize the characterization of biological activity and identify relevant off-target effects that could hinder the clinical efficacy of the compound when tested in human subjects. A successful drug discovery strategy in PAH will require collaboration of clinician scientists with medicinal chemists and pharmacologists who can identify compounds with an adequate safety profile and biological activity against relevant disease mechanisms. |*Drug Design [MESH] |Animals [MESH] |Cooperative Behavior [MESH] |Drug Discovery/*methods [MESH] |Drug Evaluation, Preclinical/methods [MESH] |Humans [MESH]Novel approaches to pulmonary arterial hypertension drug discovery (epmc).pdf DeepDyve Pubget Overpricing